Stifel Nicolaus Issues Positive Forecast for 908 Devices (NASDAQ:MASS) Stock Price

908 Devices (NASDAQ:MASS) had its price target increased by Stifel Nicolaus from $12.00 to $14.00 in a report issued on Wednesday, Marketbeat reports. The brokerage currently has a buy rating on the stock.

Several other research firms have also commented on MASS. Roth Capital increased their price objective on shares of 908 Devices from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of 908 Devices in a report on Wednesday, November 4th. Canaccord Genuity Group initiated coverage on shares of 908 Devices in a research report on Thursday, September 10th. They set a “buy” rating and a $13.50 target price on the stock. Finally, Wall Street Zen downgraded shares of 908 Devices from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, 908 Devices presently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

908 Devices Price Performance

NASDAQ:MASS opened at $10.06 on Wednesday. The company has a market cap of $415.82 million, a price-to-earnings ratio of -15.48 and a beta of 0.66. 908 Devices has a 1 year low of $5.03 and a 1 year high of $13.35. The stock’s 50 day simple moving average is $11.18 and its two-hundred day simple moving average is $8.53.

908 Devices (NASDAQ:MASS) last posted its earnings results on Tuesday, November 10th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. 908 Devices had a negative net margin of 36.87% and a negative return on equity of 11.76%. The firm had revenue of $18.95 million during the quarter, compared to analyst estimates of $18.31 million. As a group, analysts anticipate that 908 Devices will post -0.59 EPS for the current year.

Insider Activity at 908 Devices

In other 908 Devices news, Director Christopher Brown sold 30,000 shares of 908 Devices stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $10.95, for a total transaction of $328,500.00. Following the completion of the transaction, the director directly owned 775,559 shares of the company’s stock, valued at $8,492,371.05. The trade was a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP John Kenneweg sold 5,257 shares of 908 Devices stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $10.22, for a total transaction of $53,726.54. Following the transaction, the senior vice president directly owned 57,784 shares of the company’s stock, valued at $590,552.48. The trade was a 8.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 134,115 shares of company stock worth $1,473,296. Company insiders own 28.20% of the company’s stock.

Institutional Investors Weigh In On 908 Devices

Hedge funds and other institutional investors have recently made changes to their positions in the company. Pier 88 Investment Partners LLC boosted its stake in shares of 908 Devices by 59.2% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 22,600 shares of the company’s stock worth $279,000 after purchasing an additional 8,400 shares during the period. First Light Asset Management LLC raised its position in 908 Devices by 3.5% in the 2nd quarter. First Light Asset Management LLC now owns 6,282,804 shares of the company’s stock worth $54,660,000 after purchasing an additional 210,241 shares during the period. Gainline Financial Partners LLC purchased a new stake in 908 Devices in the 2nd quarter worth about $107,000. AXQ Capital LP purchased a new stake in 908 Devices in the 2nd quarter worth about $93,000. Finally, Bank of America Corp DE purchased a new stake in 908 Devices in the 2nd quarter worth about $2,184,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Key Stories Impacting 908 Devices

These are some of the MASS stories that stood out recently:

• Positive Sentiment: 908 Devices reported record Q3 revenue of about $19 million, up 35% year over year, and record device shipments. Its loss of $0.11 per share was smaller than the expected $0.15–$0.16 loss, while revenue exceeded the $18.31 million estimate. These results may bolster investor confidence in growth. Company earnings release
• Neutral Sentiment: Management’s FY 2026 revenue guidance of $68.5 million–$70 million brackets the $69.1 million consensus estimate, offering no clear change in expectations. Company earnings release
• Negative Sentiment: Despite the better-than-expected quarter, 908 Devices continues to report losses, with a negative net margin of 56.96%, highlighting ongoing profitability risk.

908 Devices Company Profile

908 Devices, Inc. develops analytical instruments that help users identify and measure chemicals and biomolecules. Its products use mass spectrometry and related technologies to bring laboratory-style analysis to settings where rapid results are needed. The company’s portfolio includes handheld devices for detecting and identifying chemical substances, as well as laboratory instruments and tools used in areas such as biopharmaceutical research and protein analysis. Its customers include organizations in public safety, defense, forensics, industrial markets and life sciences.